trastuzumab,pertuzumab
roche
['phergain', ' ribo', 'bcsm']
bottom line from #asco23 for bc: can give cdk46 as second line in the lower risk patients; fixed lower dose cape as good and less toxic; adjuvant ribo shows early benefit; ofs in younger patients shows benefit; it s time to do smaller bio marker trials like #phergain. #bcsm
Oncologist and tennis player